NCT00946114View on ClinicalTrials.gov

To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Pulmonary Hypertension

Interventions

DRUG

sildenafil

tablets, 20mg, TID, 112 weeks at the maximum

DRUG

sildenafil

tablets, 20mg x 4 (80mg), TID, approximately 70 weeks

Trial Locations (2)

01-138

Pfizer Investigational Site, Warsaw

41-800

Pfizer Investigational Site, Zabrze

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00946114 - To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks | Biotech Hunter | Biotech Hunter